CAT-4001 is being developed by Catabasis as a potential treatment for neurodegenerative diseases, such as FA and amyotrophic lateral sclerosis (ALS). CAT-4001 is a small molecule that activates Nrf2 and inhibits NF-kB, two pathways that have been ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.